How the current West African Ebola epidemic is altering views on the need for vaccines and is galvanizing a global effort to field test leading candidates

Myron M. Levine, Milagritos Tapia, Adrian V. Hill, et al.

14 September 2014, Advance Access

DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild Type Glycoproteins are Safe and Immunogenic in a Phase I Clinical Trial

Uzma N. Sarwar, Pamela Costner, Mary E. Enama, et al.

14 September 2014, Advance Access



A Practical Treatment for Patients with Ebola Virus Disease

David S. Fedson

25 August 2014; Advance Access



Reply to Fedson

Anita K. McElroy and Christina F Spiropoulou

25 August 2014; Advance Access



Ebola Hemorrhagic Fever: Novel Biomarker Correlates of Clinical Outcome

Anita K. McElroy, Bobbie R. Erickson, Timothy D. Flietstra, et al.

15 August 2014; 210 (4): 558 - 566

Interferon-β Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever

Lauren M. Smith, Lisa E. Hensley, Thomas W. Geisbert, et al.

15 July 2013; 208 (2): 310 - 318

A Syrian Golden Hamster Model Recapitulating Ebola Hemorrhagic Fever

Hideki Ebihara, Marko Zivcec, Donald Gardner, et al.

15 January 2013; 207 (2): 306 - 318

Reston ebolavirus in Humans and Animals in the Philippines: A Review

Mary Elizabeth G. Miranda and Noel Lee J. Miranda

1 November 2011; 204: S757 - S760

Management of Accidental Exposure to Ebola Virus in the Biosafety Level 4 Laboratory, Hamburg, Germany

Stephan Günther, Heinz Feldmann, Thomas W. Geisbert, et al.

1 November 2011; 204: S785 - S790

Ebola Reston Virus Infection of Pigs: Clinical Significance and Transmission Potential

Glenn A. Marsh, Jessica Haining, Rachel Robinson, et al.

1 November 2011; 204: S804 - S809

Basic Clinical and Laboratory Features of Filoviral Hemorrhagic Fever

Mark G. Kortepeter, Daniel G. Bausch, and Mike Bray

1 November 2011; 204: S810 - S816

Characterization of Filovirus Protein–Protein Interactions in Mammalian Cells Using Bimolecular Complementation

Yuliang Liu, Sasha Stone, and Ronald N. Harty

1 November 2011; 204: S817 - S824

Comparative Analysis of Ebola Virus Glycoprotein Interactions With Human and Bat Cells

Annika Kühl, Markus Hoffmann, Marcel A. Müller, et al.

1 November 2011; 204: S840 - S849

DRBP76 Associates With Ebola Virus VP35 and Suppresses Viral Polymerase Function

Reed S. Shabman, Daisy W. Leung, Joshua Johnson, et al.

1 November 2011; 204: S911 - S918

Real-time Monitoring of Cardiovascular Function in Rhesus Macaques Infected With Zaire ebolavirus

Mark G. Kortepeter, James V. Lawler, Anna Honko et al.

1 November 2011; 204: S1000 - S1010

The Importance of the NP: VP35 Ratio in Ebola Virus Nucleocapsid Formation

Takeshi Noda, Larissa Kolesnikova, Stephan Becker, et al.

1 November 2011; 204: S878 - S883

Role of VP30 Phosphorylation in the Ebola Virus Replication Cycle

Miguel J. Martinez, Valentina A. Volchkova, Hervé Raoul, et al.

1 November 2011; 204: S934 - S940

Ebola Virus Failure to Stimulate Plasmacytoid Dendritic Cell Interferon Responses Correlates With Impaired Cellular Entry

Lawrence W. Leung, Osvaldo Martinez, Olivier Reynard, et al.

1 November 2011; 204: S973 - S977

Filovirus Infection of STAT-1 Knockout Mice

JoLynne Raymond, Steven Bradfute, and Mike Bray

1 November 2011; 204: S986 - S990

Host Response Dynamics Following Lethal Infection of Rhesus Macaques With Zaire ebolavirus

Hideki Ebihara, Barry Rockx, Andrea Marzi, et al.

1 November 2011; 204: S991 - S999

VP24 Is a Molecular Determinant of Ebola Virus Virulence in Guinea Pigs

Mathieu Mateo, Caroline Carbonnelle, Olivier Reynard, et al.

1 November 2011; 204: S1011 - S1020.

Kunjin Virus Replicon-Based Vaccines Expressing Ebola Virus Glycoprotein GP Protect the Guinea Pig Against Lethal Ebola Virus Infection

O. Reynard, V. Mokhonov, E. Mokhonova, J. Leung, et al.

1 November 2011; 204: S1060 - S1065.

Emergence of Divergent Zaire Ebola Virus Strains in Democratic Republic of the Congo in 2007 and 2008

Gilda Grard, Roman Biek, Jean-Jacques Muyembe Tamfum, et al.

1 November 2011; 204: S776 - S784.

Impact of Ebola Mucin-Like Domain on Antiglycoprotein Antibody Responses Induced by Ebola Virus-Like Particles

Osvaldo Martinez, Lee Tantral, Nirupama Mulherkar, et al.

1 November 2011; 204: S825 - S832.

Conserved Proline-Rich Region of Ebola Virus Matrix Protein VP40 Is Essential for Plasma Membrane Targeting and Virus-Like Particle Release

Olivier Reynard, Kirill Nemirov, Audrey Page, et al.

1 November 2011; 204: S884 - S891.

Contribution of Sec61α to the Life Cycle of Ebola Virus

Ayaka Iwasa, Peter Halfmann, Takeshi Noda, et al.

1 November 2011; 204: S919 - S926.

Antibody-Dependent Enhancement of Marburg Virus Infection

Eri Nakayama, Daisuke Tomabechi, Keita Matsuno, et al.

1 November 2011; 204: S978 - S985.

Ebola Virus as a Foodborne Pathogen? Cause for Consideration, but Not Panic

Daniel G. Bausch

15 July 2011; 204 (2): 179 - 181.

Therapeutics of Ebola Hemorrhagic Fever: Whole-Genome Transcriptional Analysis of Successful Disease Mitigation

Judy Y. Yen, Sara Garamszegi, Joan B. Geisbert, et al.

1 November 2011; 204: S1043 - S1052.

2011 Supplement on Filoviruses

2007 Supplement on Filoviruses